A Phase 1 interventional study of REGN5381 and Placebo in Healthy, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of REGN5381 in healthy normotensive and otherwise healthy hypertensive adults.
The secondary objectives of the study are:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTE: Additional Inclusion / Exclusion criteria apply
Single dose REGN5381 administered via IV infusion
Drug: REGN5381
Placebo matching single dose REGN 5381 administered via IV infusion
Other: Placebo
Single dose REGN5381 administered via IV infusion
Placebo matching single dose REGN 5381 administered via IV infusion
Incidence of Treatment-Emergent Adverse Events
Time frame: Up to Day 78
Change from baseline in Systolic Blood Pressure (SBP)
Time frame: Up to Day 78
Change from baseline in Diastolic Blood Pressure (DBP)
Time frame: Up to Day 78
Change from baseline in Mean Arterial Pressure (MAP)
Time frame: Baseline to Day 4
Change from baseline in Pulse Pressure (PP)
Time frame: Baseline to Day 4
Change from baseline in Heart Rate (HR)
Time frame: Up to Day 78
Change from baseline in Stroke Volume (SV)
Time frame: Baseline to Day 4
Maximum change from baseline in SBP across the first 24 hours postdose
Time frame: Baseline to Day 2 (24-hours post dose)
Maximum change from baseline in DBP across the first 24 hours postdose
Time frame: Baseline to Day 2 (24-hours post dose)
Maximum change from baseline in MAP across the first 24 hours postdose
Time frame: Baseline to Day 2 (24-hours post dose)
Maximum change from baseline in PP across the first 24 hours postdose
Time frame: Baseline to Day 2 (24-hours post dose)
Maximum change from baseline in HR across the first 24 hours postdose
Time frame: Baseline to Day 2 (24-hours post dose)
Maximum change from baseline in SV across the first 24 hours postdose
Time frame: Baseline to Day 2 (24-hours post dose)
Change from baseline in the 24-hour mean SBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Baseline 24-hour mean SBP is measured from 0 to 24 hours pre-dose
Time frame: Baseline to 24 hours postdose, 24 hours to 48 hours postdose, 48 hours to 72 hours postdose
Change from baseline in the 24-hour mean DBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Baseline 24-hour mean DBP is measured from 0 to 24 hours pre-dose
Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Change from baseline in the 24-hour mean MAP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Baseline 24-hour mean MAP is measured from 0 to 24 hours pre-dose
Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Change from baseline in the 24-hour mean PP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Baseline 24-hour mean PP is measured from 0 to 24 hours pre-dose
Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Change from baseline in the 24-hour mean HR measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Baseline 24-hour mean HR is measured from 0 to 24 hours pre-dose
Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose
Concentrations of REGN5381 over time
Time frame: Up to Day 78
Number of subjects who develop anti-drug antibodies (ADA) and titers
Time frame: Up to Day 78
Percentage of subjects who develop anti-drug antibodies (ADA) and titers
Time frame: Up to Day 78
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Dec 2022, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vixticibart